Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung Cancer Stage III
Interventions
RADIATION

radiotherapy

"Radiotherapy techniques: Volumetric-modulated arc therapy (VMAT) and image guided radiotherapy (IGRT).~Radiotherapy dose: Radical prescription dose of 60 gray (Gy) ± 10%, 2 Gy per session, once a day, 5 days a week."

DRUG

Platinum-Based Drug

Cisplatin 25 mg/m2 once per week for a total of 5-6 cycles. For participants who have not completed 4 cycles of conversion chemotherapy in combination with immunotherapy, the original chemotherapy regimen may also be used, with the total number of chemotherapy cycles not exceeding 6 cycles.

DRUG

Immunotherapy

Concurrent programmed cell death 1 (PD-1) or programmed cell death L1 (PD-L1) inhibitors every 3 weeks during radiotherapy and no more than 3 doses during the course of radiotherapy.

DRUG

Immunotherapeutic Agent

All participants will be evaluated within 1-42 days after receiving radiation (chemotherapy). If disease progression does not occur, adjuvant therapy with a PD-1 or PD-L1 inhibitor is continued until disease progression up to 1 year.

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT06031597 - Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy | Biotech Hunter | Biotech Hunter